News & Media

20232022202120202019201820172016201520142013
Press release 2023/05/31 Regulatory
Change in the number of shares and votes in Medivir AB (publ)

Stockholm – Medivir AB (publ) (“Medivir”) (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has...

Read more
Press release 2023/05/30
Medivir to present at the ABGSC Life Science Summit

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/05/16
Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023

In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) (“Medivir”) on 4 May 2023...

Read more
Press release 2023/05/04 Regulatory
Execution of the annual general meeting’s resolution on the removal of share class in Medivir AB (publ)

The annual general meeting in Medivir AB (publ), held earlier today on 4 May 2023, resolved to adopt new articles of...

Read more
Press release 2023/05/04 Regulatory
Resolutions at the Annual General Meeting in Medivir on 4 May 2023

Medivir Aktiebolag (publ) held its annual general meeting today on 4 May 2023. The annual general meeting was held by physical...

Read more
Press release 2023/04/27 Regulatory
MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2023

“Thanks to the strong interest from clinicians and patients, we were able to swiftly dose the first patients in the phase...

Read more
Press release 2023/04/17
Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/04/04 Regulatory
Medivir 2022 Annual Report published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2022 now is available at the...

Read more
Press release 2023/03/31 Regulatory
Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the...

Read more
Press release 2023/03/17
Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/03/14
First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2023/03/08
Medivir to present at the Stockholm Corporate Finance Life Science Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more